UA83790C2 - Применение sarp-1 для лечения и/или предупреждения фиброзных заболеваний - Google Patents

Применение sarp-1 для лечения и/или предупреждения фиброзных заболеваний

Info

Publication number
UA83790C2
UA83790C2 UA2003076266A UA2003076266A UA83790C2 UA 83790 C2 UA83790 C2 UA 83790C2 UA 2003076266 A UA2003076266 A UA 2003076266A UA 2003076266 A UA2003076266 A UA 2003076266A UA 83790 C2 UA83790 C2 UA 83790C2
Authority
UA
Ukraine
Prior art keywords
sarp
prevention
treatment
fibrotic diseases
fibrosis
Prior art date
Application number
UA2003076266A
Other languages
English (en)
Ukrainian (uk)
Inventor
Кристин Платер-Зиберк
Жак Колинж
Original Assignee
Лаборатуар Сероно С.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Лаборатуар Сероно С.А. filed Critical Лаборатуар Сероно С.А.
Publication of UA83790C2 publication Critical patent/UA83790C2/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/21Interferons [IFN]
    • A61K38/215IFN-beta
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/04Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
UA2003076266A 2000-12-06 2001-11-30 Применение sarp-1 для лечения и/или предупреждения фиброзных заболеваний UA83790C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP00126771 2000-12-06
EP01118888 2001-08-17
PCT/EP2001/013992 WO2002046225A2 (en) 2000-12-06 2001-11-30 Use of sarp-1 for the treatment and/or prevention of scleroderma

Publications (1)

Publication Number Publication Date
UA83790C2 true UA83790C2 (ru) 2008-08-26

Family

ID=26071647

Family Applications (1)

Application Number Title Priority Date Filing Date
UA2003076266A UA83790C2 (ru) 2000-12-06 2001-11-30 Применение sarp-1 для лечения и/или предупреждения фиброзных заболеваний

Country Status (30)

Country Link
US (2) US7341995B2 (ru)
EP (2) EP1806144A3 (ru)
JP (1) JP2004525869A (ru)
KR (1) KR100804885B1 (ru)
CN (1) CN1323716C (ru)
AT (1) ATE359808T1 (ru)
AU (2) AU2002226366B2 (ru)
BG (1) BG107941A (ru)
BR (1) BR0115983A (ru)
CA (1) CA2428092A1 (ru)
CY (1) CY1107687T1 (ru)
CZ (1) CZ20031855A3 (ru)
DE (1) DE60128009T2 (ru)
DK (1) DK1411970T3 (ru)
EA (1) EA005973B1 (ru)
EE (1) EE200300213A (ru)
ES (1) ES2281463T3 (ru)
HK (1) HK1068106A1 (ru)
HR (1) HRP20030426A2 (ru)
HU (1) HUP0302738A3 (ru)
IL (1) IL156069A0 (ru)
MX (1) MXPA03005027A (ru)
NO (1) NO20032597D0 (ru)
NZ (1) NZ525774A (ru)
PL (1) PL365316A1 (ru)
PT (1) PT1411970E (ru)
SK (1) SK8472003A3 (ru)
UA (1) UA83790C2 (ru)
WO (1) WO2002046225A2 (ru)
YU (1) YU45103A (ru)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7026445B2 (en) * 1997-02-06 2006-04-11 Genetics Institute, Llc Human SDF-5 protein and compositions
US7585840B2 (en) 2002-04-10 2009-09-08 Merck Serono S.A. Use of osteoprotegerin for the treatment and/or prevention of fibrotic disease
CN1658895A (zh) * 2002-04-10 2005-08-24 应用研究系统Ars股份公司 护骨素在治疗和/或预防纤维变性疾病中的应用
US9046537B2 (en) * 2003-09-22 2015-06-02 Enzo Biochem, Inc. Method for treating inflammation by administering a compound which binds LDL-receptor-related protein (LRP) ligand binding domain
SE0400489D0 (sv) * 2004-02-27 2004-02-27 Biovitrum Ab Therapeutic proteins
TR201901929T4 (tr) * 2005-02-08 2019-03-21 Genzyme Corp TGFBeta'ya antikorlar.
EP1948210A4 (en) * 2005-11-08 2010-07-14 Found Biomedical Res & Innov METHOD FOR TREATING ISCHEMIC HEART DISEASE
US20100260785A1 (en) * 2007-12-13 2010-10-14 Gabriela Saborio SARP-1 Fusion Proteins and Uses Thereof
CN107375293A (zh) * 2011-03-11 2017-11-24 细胞基因公司 利用3‑(5‑氨基‑2‑甲基‑4‑氧‑4h‑喹唑啉‑3‑基)‑哌啶‑2,6‑二酮治疗癌症的方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2855189A (en) * 1988-01-25 1989-07-27 Baker Cummins Dermatologicals, Inc. Method of treating fibrotic disorders
US5266575A (en) * 1991-11-06 1993-11-30 Minnesota Mining And Manufacturing Company 2-ethyl 1H-imidazo[4,5-ciquinolin-4-amines
US5747639A (en) * 1996-03-06 1998-05-05 Amgen Boulder Inc. Use of hydrophobic interaction chromatography to purify polyethylene glycols
TW555765B (en) * 1996-07-09 2003-10-01 Amgen Inc Low molecular weight soluble tumor necrosis factor type-I and type-II proteins
ES2263181T5 (es) * 1996-09-24 2011-04-07 Genentech, Inc. Una familia de genes que codifican péptidos relacionados con la apoptosis, péptidos codificados por ellos y los métodos de uso de los mismos.
US5858715A (en) * 1997-01-29 1999-01-12 Incyte Pharmaceuticals, Inc. Human apoptosis-associated protein
US7026445B2 (en) * 1997-02-06 2006-04-11 Genetics Institute, Llc Human SDF-5 protein and compositions
PT1121382E (pt) * 1998-10-16 2006-10-31 Biogen Idec Inc Proteinas de fusao do interferao beta e as respectivas utilizacoes

Also Published As

Publication number Publication date
EP1411970A2 (en) 2004-04-28
ATE359808T1 (de) 2007-05-15
US20080107627A1 (en) 2008-05-08
CN1553806A (zh) 2004-12-08
HRP20030426A2 (en) 2005-04-30
DE60128009T2 (de) 2007-08-23
KR20030076585A (ko) 2003-09-26
WO2002046225A2 (en) 2002-06-13
EP1806144A3 (en) 2008-04-23
CZ20031855A3 (cs) 2003-09-17
DE60128009D1 (de) 2007-05-31
EA005973B1 (ru) 2005-08-25
YU45103A (sh) 2006-08-17
AU2002226366B2 (en) 2007-03-22
BG107941A (bg) 2004-01-30
ES2281463T3 (es) 2007-10-01
IL156069A0 (en) 2003-12-23
BR0115983A (pt) 2003-12-30
HUP0302738A2 (hu) 2003-11-28
NO20032597L (no) 2003-06-06
EP1411970B1 (en) 2007-04-18
PL365316A1 (en) 2004-12-27
HK1068106A1 (en) 2005-04-22
HUP0302738A3 (en) 2010-01-28
SK8472003A3 (en) 2003-10-07
AU2636602A (en) 2002-06-18
US7655628B2 (en) 2010-02-02
KR100804885B1 (ko) 2008-02-20
EE200300213A (et) 2003-08-15
US20050113291A1 (en) 2005-05-26
DK1411970T3 (da) 2007-06-04
NZ525774A (en) 2006-03-31
CA2428092A1 (en) 2002-06-13
CY1107687T1 (el) 2012-05-23
WO2002046225A3 (en) 2004-01-08
CN1323716C (zh) 2007-07-04
JP2004525869A (ja) 2004-08-26
PT1411970E (pt) 2007-05-31
US7341995B2 (en) 2008-03-11
EP1806144A2 (en) 2007-07-11
EA200300639A1 (ru) 2003-12-25
NO20032597D0 (no) 2003-06-06
MXPA03005027A (es) 2003-09-05

Similar Documents

Publication Publication Date Title
UA56989C2 (ru) ФИЗИОЛОГИЧЕСКИ АКТИВНЫЙ ПЕГ-КОНЬЮГАТ a-ИНТЕРФЕРОНА, СПОСОБ ЕГО ПОЛУЧЕНИЯ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ НА ЕГО ОСНОВЕ И СПОСОБ ЛЕЧЕНИЯ ИЛИ ПРОФИЛАКТИКИ ИММУНОМОДУЛЯТОРНЫХ ЗАБОЛЕВАНИЙ
WO2002087563A3 (en) Compositions comprising an anti-microtubule agent and a polypeptide or a polysaccharide and the use thereof for the preparation of a medicament for the treatment of inflammatory conditions
HUP0301815A3 (en) Mono and disaccharide-based pharmaceutical composition for infections and other diseases and prophylactic and therapeutic treatment
BG106095A (en) Novel medicament compositions, based on anticholinergically effective compounds and beta-mimetics
HUP0102899A3 (en) Process for preparation of compositions for the application of anti-inflammatory, especially antiseptic agents and/or agents promoting the healing of wounds, to the lower respiratory tract
HK1178800A1 (zh) 預防和治療腦膜炎球菌性疾病的新型免疫原性組合物
BG108443A (en) Substituted oxazoliidinones for combinational therapy
CA2292359A1 (en) Novel azalides and methods of making same
AU6286294A (en) Guanidine derivatives useful in therapy
CA2289717A1 (en) Novel therapy for constipation
EP1461024A4 (en) TREATMENT OF WOUNDS AND COMPOSITIONS USED
WO1999043344A3 (en) Matrix protein compositions for wound healing
AU2002248319A1 (en) Pharmaceutical composition for the prevention and treatment of scar tissue
UA83790C2 (ru) Применение sarp-1 для лечения и/или предупреждения фиброзных заболеваний
WO2001024783A3 (de) Verwendung von (+)-tramadol, o-demethyltramadol bzw. (+)-o-demethyltramadol, o-desmethyl-n-mono-desmethyl-tramadol bzw. (+)-o-desmethyl-n-mono-desmethyl-tramadol zur therapie der harninkontinenz
AU2002227052A1 (en) Treatments for neurogenetic disorders, impulse control disorders, and wound healing
WO2001081332A3 (en) 2-fluorobenzenesulfonyl compounds for the treatment of inflammation
EP2138175A3 (en) Formulations comprising valsartan for treating diabetes or microalbuminuria
WO2001074394A8 (en) New combination of a betablocker and a cholesterol-lowering agent
IL162259A0 (en) Benzazole derivatives in scleroderma
WO2003000173A3 (en) Use of branched-chain fatty acids and derivatives thereof for the treatment of pain
WO2003049667A3 (en) The method of treating cancer
CA2289017A1 (en) The use of a nitroxide or a prodrug thereof in the prophylactic and therapeutic treatment of cancer
CA2399709A1 (en) Use of 2-methyl-thiazolidin-2,4-dicarboxylic acid and/or physiologically compatible salts thereof for producing a medicament for treating cancers
WO2000059490A3 (en) Immunomodulating composition for use especially in the treatment of inflammations, infections and surgical adhesions